Integral Health Asset Management LLC Has $1.31 Million Stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Integral Health Asset Management LLC lifted its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 75.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 350,000 shares of the company's stock after purchasing an additional 150,000 shares during the quarter. Integral Health Asset Management LLC owned 0.81% of Kyverna Therapeutics worth $1,309,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Jacobs Levy Equity Management Inc. lifted its position in shares of Kyverna Therapeutics by 2,225.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company's stock worth $1,728,000 after purchasing an additional 442,090 shares in the last quarter. Corton Capital Inc. bought a new stake in shares of Kyverna Therapeutics in the fourth quarter worth $45,000. Bridgeway Capital Management LLC bought a new stake in shares of Kyverna Therapeutics in the fourth quarter worth $299,000. Bank of America Corp DE lifted its position in shares of Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company's stock worth $81,000 after purchasing an additional 6,400 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Kyverna Therapeutics by 65.4% in the fourth quarter. BNP Paribas Financial Markets now owns 44,983 shares of the company's stock worth $168,000 after purchasing an additional 17,786 shares in the last quarter. Institutional investors own 18.08% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HC Wainwright lowered their target price on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a "neutral" rating on the stock in a report on Thursday, April 3rd. Morgan Stanley lowered their target price on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $18.33.

Kyverna Therapeutics Stock Performance

KYTX traded down $0.17 during trading on Wednesday, reaching $2.15. 301,060 shares of the stock were exchanged, compared to its average volume of 412,319. The stock has a market cap of $92.92 million, a P/E ratio of -0.62 and a beta of 2.17. Kyverna Therapeutics, Inc. has a twelve month low of $1.78 and a twelve month high of $17.55. The stock's 50 day moving average price is $2.17 and its two-hundred day moving average price is $3.33.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.18. Equities research analysts predict that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.